How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial

Eric L. Matteson, C. M. Weyand, J. W. Fulbright, T. J.H. Christianson, R. L. McClelland, J. J. Goronzy

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial'. Together they form a unique fingerprint.

Medicine & Life Sciences